Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ESPR Esperion Therapeutics	$1.17	$0.96	$0.69 ▼ $3.94	$231.89M	0.67	5.26 million shs	2.45 million shs
GNFT Genfit	$4.13 +0.8%	$3.99	$2.55 ▼ $6.42	$206.53M	1.15	10,832 shs	573 shs
INMB INmune Bio	$8.02 +4.2%	$7.56	$4.32 ▼ $10.50	$184.33M	1.55	289,894 shs	670,791 shs
OTLK Outlook Therapeutics	$1.77 -2.7%	$1.61	$0.87 ▼ $9.25	$59.42M	0.31	799,490 shs	482,531 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ESPR Esperion Therapeutics	0.00%	-4.10%	+45.92%	-24.03%	-60.87%
GNFT Genfit	0.00%	-1.42%	-2.15%	+14.65%	+0.24%
INMB INmune Bio	0.00%	+1.05%	-2.04%	+0.39%	-9.31%
OTLK Outlook Therapeutics	0.00%	-4.21%	+4.00%	+18.18%	-76.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ESPR Esperion Therapeutics	4.0707 of 5 stars	3.3	3.0	3.9	2.8	1.7	0.6
GNFT Genfit	2.5417 of 5 stars	3.5	5.0	0.0	3.0	0.0	0.0
INMB INmune Bio	1.8929 of 5 stars	3.6	0.0	0.0	2.6	1.7	0.6
OTLK Outlook Therapeutics	1.4107 of 5 stars	3.4	1.0	0.0	1.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ESPR Esperion Therapeutics	2.50	Moderate Buy	$6.25	434.19% Upside
GNFT Genfit	3.00	Buy	$13.00	214.69% Upside
INMB INmune Bio	3.17	Buy	$22.80	184.29% Upside
OTLK Outlook Therapeutics	2.80	Moderate Buy	$9.60	442.37% Upside

Current Analyst Ratings Breakdown

Latest OTLK, GNFT, INMB, and ESPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	OTLK Outlook Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $21.00
5/20/2025	OTLK Outlook Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00
4/8/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/20/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ESPR Esperion Therapeutics	$259.57M	0.89	N/A	N/A	($3.85) per share	-0.30
GNFT Genfit	$67.00M	3.08	N/A	N/A	$1.48 per share	2.79
INMB INmune Bio	$50K	3,686.63	N/A	N/A	$2.07 per share	3.87
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	($1.57) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ESPR Esperion Therapeutics	-$209.25M	-$0.80	N/A	N/A	N/A	-29.37%	N/A	-10.77%	8/11/2025 (Estimated)
GNFT Genfit	-$31.27M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/24/2025 (Estimated)
INMB INmune Bio	-$30.01M	-$1.93	N/A	N/A	N/A	N/A	-117.48%	-78.96%	7/30/2025 (Estimated)
OTLK Outlook Therapeutics	-$75.37M	-$0.91	N/A	N/A	N/A	N/A	N/A	-225.12%	8/13/2025 (Estimated)

Latest OTLK, GNFT, INMB, and ESPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q2 2025	OTLK Outlook Therapeutics	-$0.55	-$0.40	+$0.15	-$1.50	$0.70 million	N/A
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million
3/27/2025	Q4 2024	INMB INmune Bio	-$0.54	-$0.40	+$0.14	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
GNFT Genfit	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ESPR Esperion Therapeutics	N/A	1.85	1.37
GNFT Genfit	0.61	3.74	3.74
INMB INmune Bio	N/A	2.59	2.59
OTLK Outlook Therapeutics	N/A	0.32	0.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ESPR Esperion Therapeutics	47.39%
GNFT Genfit	2.24%
INMB INmune Bio	12.72%
OTLK Outlook Therapeutics	11.20%

Insider Ownership

Company	Insider Ownership
ESPR Esperion Therapeutics	1.70%
GNFT Genfit	4.20%
INMB INmune Bio	35.70%
OTLK Outlook Therapeutics	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ESPR Esperion Therapeutics	200	198.20 million	195.07 million	Optionable
GNFT Genfit	120	50.00 million	47.90 million	Not Optionable
INMB INmune Bio	10	22.98 million	14.37 million	Optionable
OTLK Outlook Therapeutics	20	33.57 million	30.48 million	Optionable

OTLK, GNFT, INMB, and ESPR Headlines

Recent News About These Companies

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of "Moderate Buy" from Analysts

June 16 at 3:08 AM | marketbeat.com

CFA Institute 2025 Graduate Outlook Survey: Finance Top Career Choice

June 12, 2025 | tmcnet.com

Steve Wilks Pleased With Jets Defensive Outlook

June 12, 2025 | msn.com

Microsoft Outlook to block more risky attachments used in attacks

June 12, 2025 | bleepingcomputer.com

Outlook’s wet AMD treatment accepted by SMC for NHS Scotland

June 11, 2025 | pharmaceutical-technology.com

Outlook Therapeutics, Inc.: Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD

June 10, 2025 | finanznachrichten.de

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

June 10, 2025 | globenewswire.com

Highlights | Outlook Planet’s C³ Summit & Awards 2025

June 7, 2025 | outlookbusiness.com

Natural Gas Price Outlook – Natural Gas Continues to See Same Resistance Level

June 7, 2025 | fxempire.com

Oilers' Connor McDavid Offers Hilarious Outlook on Crucial Game 1 Moment

June 7, 2025 | msn.com

ChatGPT Business Features Now Include Gmail/Outlook Connectors, Meeting Transcriptions, New Pricing

June 7, 2025 | techrepublic.com

Outlook Therapeutics (NASDAQ:OTLK) Given New $21.00 Price Target at Ascendiant Capital Markets

June 6, 2025 | marketbeat.com

Outlook Therapeutics introduces Lytenava in Germany & UK for the treatment of wet AMD

June 4, 2025 | pharmabiz.com

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

June 2, 2025 | globenewswire.com

Q3 EPS Estimate for Outlook Therapeutics Boosted by Analyst

May 31, 2025 | marketbeat.com

Brookline Capital Management Forecasts OTLK FY2026 Earnings

May 30, 2025 | marketbeat.com

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Rating of "Moderate Buy" by Analysts

May 24, 2025 | marketbeat.com

Outlook Therapeutics announces public stock offering

May 24, 2025 | investing.com

Outlook Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and Warrants

May 24, 2025 | nasdaq.com

Outlook Therapeutics announces proposed public offering of common stock, warrants

May 23, 2025 | msn.com

Outlook Therapeutics drops 17%, prices $13M stock offering

May 23, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK, GNFT, INMB, and ESPR Company Descriptions

Esperion Therapeutics NASDAQ:ESPR

$1.17 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.17 0.00 (0.00%)

As of 07:27 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Genfit NASDAQ:GNFT

$4.13 +0.03 (+0.76%)

As of 03:50 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

INmune Bio NASDAQ:INMB

$8.02 +0.32 (+4.16%)

Closing price 04:00 PM Eastern

Extended Trading

$7.87 -0.15 (-1.86%)

As of 07:25 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Outlook Therapeutics NASDAQ:OTLK

$1.77 -0.05 (-2.75%)

Closing price 04:00 PM Eastern

Extended Trading

$1.78 +0.00 (+0.28%)

As of 07:19 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time